Head to Head Survey: Uroplasty (UPI) vs. Its Rivals
Uroplasty (NASDAQ: UPI) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Uroplasty to similar companies based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends.
This is a breakdown of recent ratings for Uroplasty and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical Devices & Implants” companies have a potential upside of 37.64%. Given Uroplasty’s rivals higher possible upside, analysts clearly believe Uroplasty has less favorable growth aspects than its rivals.
Volatility and Risk
Uroplasty has a beta of -1.26, meaning that its share price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s rivals have a beta of 0.21, meaning that their average share price is 79% less volatile than the S&P 500.
Valuation & Earnings
This table compares Uroplasty and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Uroplasty Competitors||$1.67 billion||$207.58 million||67.31|
Uroplasty’s rivals have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Uroplasty and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Uroplasty rivals beat Uroplasty on 6 of the 8 factors compared.
Uroplasty Company Profile
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.